AAD
Author: Willhemenia Loremipsum Special session: Lorem ipsum dolor sit amet Category: Lorem ipsum View all results

Please login or create an account. If you do not have access to this content, you will be shown a 30 second preview and licensing options.

  • Presentation

Corticosteroid Use, Tapering, and Prophylaxis in Dermatologic and Inflammatory Disease

Description

The talk emphasized that corticosteroids remain important in dermatologic and inflammatory disease because they act quickly and broadly, but their wide immunosuppressive effects also create substantial toxicity. They should generally be used as bridge therapy rather than a long-term destination, with careful selection of agent, dose, route, and timing based on the disease being treated and patient factors such as liver, kidney, cardiac, muscle, and pregnancy status. Dosing examples ranged from moderate prednisone-equivalent doses for severe dermatoses to pulse-dose IV methylprednisolone for life-threatening flares, with morning dosing preferred to reduce insomnia and endocrine effects. The speaker reviewed tapering principles, noting that abrupt stopping is usually avoided after about 2 to 3 weeks of use, that taper speed should slow as doses approach physiologic range, and that symptoms such as fatigue or achiness can occur during taper but worsening nausea, hypotension, or profound fatigue may indicate adrenal insufficiency. The lecture then focused on monitoring and prophylaxis: baseline and ongoing assessment of bone health, glucose, blood pressure, lipids, ocular effects, mood changes, infection risk, and GI bleeding risk are important. For bone protection, early DEXA scanning, FRAX-based risk stratification in adults over 40, calcium/vitamin D, and bisphosphonates for moderate to very high risk patients were highlighted, with updated 2022 ACR guidance stressing that bone loss begins early. GI prophylaxis with a PPI was recommended when steroids are combined with NSAIDs or aspirin, or when other ulcer risk factors are present. Finally, the speaker reviewed PJP prophylaxis, especially for higher-risk patients such as those on prolonged prednisone 20 mg/day or more, those with additional immunosuppression, lung disease, malignancy, lymphopenia, or high-risk diseases like dermatomyositis and ANCA-associated vasculitis; TMP-SMX is usually first line, but shared decision-making is essential because both the infection and prophylaxis have meaningful risks. Overall, the key message was to prescribe corticosteroids with a clear plan, taper thoughtfully, and use risk-based prophylaxis to anticipate predictable complications.

View more

Conclusions

  • Systemic corticosteroids remain valuable because they work quickly and effectively, but they should be used as bridge therapy rather than a long-term destination.
  • Choice of steroid should be individualized by disease context, with attention to mineralocorticoid activity, half-life, tissue penetration, liver function, muscle risk, pregnancy, and drug interactions.
  • Steroid dosing should be purposeful, usually given in the morning, with higher-intensity regimens reserved for severe disease and pulse dosing used only for life-threatening situations.
  • Steroids should not be stopped abruptly after longer courses; tapering should be guided by dose, duration, disease control, and signs of adrenal insufficiency.
  • Monitoring must be broad and proactive because steroids can affect bone, cardiovascular risk, glucose, adrenal function, GI bleeding, infection risk, mood, and eye health.
  • Bone loss begins early with glucocorticoids, so adults starting even relatively low chronic doses should get early fracture-risk assessment and DEXA-based stratification.
  • For steroid-induced bone protection, bisphosphonates are first-line for most moderate-to-high-risk patients, while very high-risk patients may need more aggressive treatment and specialist input.
  • GI prophylaxis with a proton pump inhibitor is mainly warranted when steroids are combined with NSAIDs or aspirin, or when other peptic ulcer risk factors are present.
  • PJP prophylaxis should be reserved for patients at meaningful risk, especially those on prolonged moderate-to-high prednisone doses plus additional risk factors such as lymphopenia, rituximab, lung disease, or high-risk inflammatory disease.
  • TMP-SMX is the preferred PJP prophylaxis agent when prophylaxis is indicated, but alternatives may be used when hypersensitivity or other patient-specific concerns make TMP-SMX unsuitable.
  • The safest corticosteroid strategy is to plan ahead, monitor early, taper thoughtfully, and use risk-based prophylaxis because most serious complications are predictable and preventable.
  • Hardy, R.S. et al. Nat Rev Rheumatol 16, 133–144 (2020).
  • Caplan A et al. J Am Acad Dermatol. 2017 Jan;76(1):1-9.
  • Caplan A et al. Journal of the American Academy of Dermatology, Volume 76, Issue 1, 2017, Pages 11-16.
  • Russell MD, et al. Rheumatology (Oxford). 2023 Apr 3;62(4):e48-e88.
  • Humphrey MB et al. Arthritis Care Res (Hoboken). 2023 Dec;75(12):2405-2419.
  • Abrignani MG et al., World J Cardiol. 2023 Aug 26;15(8):375-394.
  • Zhou, Shiwei et al., JAMA, 2023.
  • LoPiccolo J. et al., JAMA Internal Medicine, 2018.
  • Stern et al. Cochrane Database Syst Rev. 2014.
  • Green et al. Mayo Clin Proc. 2007.
  • Caplan et al. in JAMA. 2023.
  • Park et al. in Ann Rheum Dis. 2018 and Arthritis Res Ther. 2019.